Sirius Medical raises €4.4M in Series A funding to launch Sirius Pintuition

Sirius Medical is excited to announce that it has successfully raised €4.4M to accelerate the commercial launch of the Sirius Pintuition System for cancer localization and to develop a pipeline of complementary products and indications. The Series A funding is provided by a syndicate led by BOM Brabant Ventures, with co-investors Curie Capital and Holland Capital. Additional funding was provided the Dutch Research Council (NWO) and the Mibiton Foundation, next to local development agencies, business angels, management and existing shareholders of Sirius.

Hubert Martens, CEO of Sirius Medical Systems noted: “We are grateful for the trust provided by our investors in the Sirius Medical team. The A-round funding enables Sirius Medical to execute on its ambitious growth plans: delivering superior localization technology to our customers and developing our further pipeline of solutions.

Sjoerd van Gorp, senior investment manager BOM Brabant Ventures noted: “As BOM we are proud to support this venture to bring optimal care to patients with breast cancer. The innovative solution developed by Sirius allows for a better value pathway, which is crucial in the health landscape of today”.

René Medema, director of The Netherlands Cancer Institute added: “It is gratifying to see how an idea that was conceived at the Netherlands Cancer Institute to improve surgical care for breast cancer patients, is now introduced to the market by our spin-out Sirius Medical to help patients around the world”.

Breast cancer localization

For patients diagnosed with breast cancer, breast conserving surgery is the cornerstone of a curative approach. As diagnostics have rapidly improved over the past decades, surgeons are facing increasingly challenging procedures as they have to locate ever smaller and earlier-stage tumours. Until now, patient-unfriendly metal anchor wires were used as surgical localization devices to guide the surgeon.

Sirius Pintuition: the next generation localization that simply makes sense

Sirius Pintuition enables breast surgeons to accurately pinpoint the tumor location during surgery while optimizing hospital workflow; it just simply makes sense. Sirius Pintuition provides surgical oncologists with a high precision, easy-to-use, and affordable solution that contributes to an improved hospital workflow. The Sirius Pintuition System is CE marked and FDA clearance is pending. The Sirius Pintuition seed can be placed up to 180 days before the surgery to mark a target within soft tissue*. During surgery, the Sirius Pintuition Probe provides highly accurate, real-time feedback and directional guidance to the marked tissue. Sirius Pintuition aims to provide all the benefits of radioactive seeds without any of its hassle.

*Please refer to the product instructions for use

About Sirius Medical

With its roots in the Netherlands Cancer Institute and the University of Twente, Sirius Medical was born to make things better. Sirius Medical recently received CE mark for their Sirius Pintuition system. Sirius Pintuition provides surgical oncologists with a highly precise, easy-to-use, and affordable solution that contributes to an improved hospital workflow.

To learn more about Sirius Pintuition and the Sirius Medical, visit